PLIANT THERAPEUTICS, INC.
PLRX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PLRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PLRX
Pliant Therapeutics is a clinical-stage biopharmaceutical company developing integrin-based therapeutics, with a lead program targeting solid tumors via TGF-β inhibition.
Key risk: No approved products
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 5 clinical trials for PLIANT THERAPEUTICS, INC..
Pliant Therapeutics is a clinical-stage biopharmaceutical company developing integrin-based therapeutics, with a lead program targeting solid tumors via TGF-β inhibition.
- Lead product candidate PLN-101095 is an oral, small molecule, dual integrin inhibitor for solid tumors [sec_mda · as of 2026-08-11].
- Cash and equivalents of $26.4M as of 2026-06-30, with net income of -$22.4M for the same period [sec].
- Accumulated deficit of $901.8M as of June 30, 2026 [sec_mda · as of 2026-08-11].
- Shareholders' equity of $181.2M as of 2026-06-30 [sec].
- Completed a $288M public common stock follow-on offering in 2024 [sec · filed 2024-04-22].
What works
- Strong cash position with $159.6M in cash, cash equivalents, and short-term investments as of June 30, 2026, providing runway for clinical development [sec_mda · as of 2026-08-11].
- Lead candidate PLN-101095 is advancing in clinical trials, with a Phase 1 trial evaluating doses up to 1000 mg three times daily [sec_mda · as of 2025-05-08].
- Proprietary drug discovery platform based on integrin biology has broad applicability across multiple disease areas [sec_mda · as of 2026-08-11].
What to weigh
- Significant accumulated deficit of $901.8M as of June 30, 2026, reflecting ongoing losses [sec_mda · as of 2026-08-11].
- Net loss of $22.4M for the quarter ended June 30, 2026, indicating continued cash burn [sec].
- Workforce reduction of approximately 45% announced in May 2025, signaling cost-cutting measures [sec_mda · as of 2025-05-08].
- No approved products or revenue streams, with all candidates in clinical stages [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
Lead candidate is PLN-101095, an oral small molecule dual integrin inhibitor for solid tumors.
“Our wholly owned lead product candidate, PLN-101095, is an oral, small molecule, dual”
SEC MD&A · August 11, 2026
Accumulated deficit of $901.8 million as of June 30, 2026.
“As of June 30, 2026, we had an accumulated deficit of $901.8 million”
SEC MD&A · August 11, 2026
Cash, cash equivalents, and short-term investments of $159.6 million as of June 30, 2026.
“cash, cash equivalents, and short-term investments of $159.6 million”
SEC MD&A · August 11, 2026
Workforce reduction of approximately 45% announced in May 2025.
“the Company announced a strategic realignment of its operations including an approximately 45% reduction in its workforce”
SEC MD&A · May 8, 2025
Risks & what to watch (4)›
Key risks
- No approved products — All product candidates are in clinical stages; no revenue from product sales [sec_mda · as of 2026-08-11].
- Significant accumulated deficit — Accumulated deficit of $901.8M as of June 30, 2026, indicating sustained losses [sec_mda · as of 2026-08-11].
- Cash burn and funding needs — Net loss of $22.4M in Q2 2026; may need additional funds sooner than planned [sec].
- Clinical trial risks
What to watch
- Progress of PLN-101095 Phase 1 trial, including dose escalation and safety data [sec_mda · as of 2025-05-08].
- Cash runway updates and any additional financing activities [sec_mda · as of 2026-08-11].
- Regulatory milestones for PLN-101095 or other candidates [sec_mda · as of 2026-08-11].
- Updates on strategic realignment and cost-saving measures [sec_mda · as of 2025-05-08].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run PLIANT THERAPEUTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PLIANT THERAPEUTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
36.1 months
D/E 0.29 · 0% dilution
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
89
Total value held
$57.2M
| Holder | Shares | Value |
|---|---|---|
| tang capital management llc | 6,143,132 | $7.7M |
| vanguard capital management llc | 4,686,202 | $5.9M |
| woodline partners lp | 3,333,660 | $4.2M |
| citadel advisors llc | 3,263,399 | $4.1M |
| adar1 capital management, llc | 2,585,126 | $3.3M |
| two sigma investments, lp | 2,253,138 | $2.8M |
| renaissance technologies llc | 1,852,842 | $2.3M |
| prosight management, lp | 1,667,600 | $2.1M |
| bml capital management, llc | 1,546,137 | $1.9M |
| peapod lane capital llc | 1,288,578 | $1.6M |
Showing top 10 of 89 institutional holders of PLIANT THERAPEUTICS, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 6.0%
- Days to cover
- 7.8
- Shares short
- 3,640,410
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PLRX short interestGovernance
Frequently asked questions
What is the AI investment thesis for PLIANT THERAPEUTICS, INC.?
Pliant Therapeutics is a clinical-stage biopharmaceutical company developing integrin-based therapeutics, with a lead program targeting solid tumors via TGF-β inhibition.
What is PLIANT THERAPEUTICS, INC.'s lead drug candidate?
PLIANT THERAPEUTICS, INC.'s most advanced tracked candidate is Bexotegrast (PLN-74809) (Phase 2) for Idiopathic Pulmonary Fibrosis; Primary Sclerosing Cholangitis.
Who is the CEO of PLIANT THERAPEUTICS, INC.?
Dr. Bernard Coulie M.B.A., M.D., Ph.D. is the chief executive officer of PLIANT THERAPEUTICS, INC. (PLRX).
Where is PLIANT THERAPEUTICS, INC. headquartered?
PLIANT THERAPEUTICS, INC. (PLRX) is headquartered in South San Francisco, CA, United States.
What therapeutic areas does PLIANT THERAPEUTICS, INC. focus on?
PLIANT THERAPEUTICS, INC. develops therapies across Oncology, Respiratory, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.